In last trading session, Capricor Therapeutics Inc (NASDAQ:CAPR) saw 0.7 million shares changing hands with its beta currently measuring 4.52. Company’s recent per share price level of $13.23 trading at $0.44 or 3.44% at ring of the bell on the day assigns it a market valuation of $601.57M. That closing price of CAPR’s stock is at a discount of -76.87% from its 52-week high price of $23.40 and is indicating a premium of 73.39% from its 52-week low price of $3.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.67 million shares which gives us an average trading volume of 1.15 million if we extend that period to 3-months.
For Capricor Therapeutics Inc (CAPR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.09 in the current quarter.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
Upright in the green during last session for gaining 3.44%, in the last five days CAPR remained trading in the green while hitting it’s week-highest on Thursday, 03/13/25 when the stock touched $13.23 price level, adding 1.42% to its value on the day. Capricor Therapeutics Inc’s shares saw a change of -4.13% in year-to-date performance and have moved 3.28% in past 5-day. Capricor Therapeutics Inc (NASDAQ:CAPR) showed a performance of -12.09% in past 30-days. Number of shares sold short was 8.17 million shares which calculate 8.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 15 to the stock, which implies a rise of 11.8% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 21.5. It follows that stock’s current price would jump 24.41% in reaching the projected high whereas dropping to the targeted low would mean a gain of 24.41% for stock’s current value.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
This year revenue growth is estimated to fall -16.70% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.87M for the same. And 3 analysts are in estimates of company making revenue of 5.5M in the next quarter. Company posted 12.09M and 4.91M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 30.59% during past 5 years.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Insiders are in possession of 16.84% of company’s total shares while institution are holding 38.26 percent of that, with stock having share float percentage of 46.01%. Investors also watch the number of corporate investors in a company very closely, which is 38.26% institutions for Capricor Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CAPR for having 1.63 million shares of worth $7.77 million. And as of 2024-06-30, it was holding 5.194 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.55 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.9401 of outstanding shares, having a total worth of $7.39 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.44 shares of worth $19.04 million or 3.16% of the total outstanding shares. The later fund manager was in possession of 1.13 shares on Dec 31, 2024 , making its stake of worth around $14.99 million in the company or a holder of 2.49% of company’s stock.
